PATIENTS
PATIENTS
Clinical Trials
Our clinical trials help to advance the understanding of innovative medicines and determine whether the new treatments being developed are safe and effective.
We know that the decision to participate in clinical trial research is not made lightly, and we sincerely thank all the patients and families who choose to participate. Your physician is the best person to help you decide if a clinical trial or any other treatment option is right for you.
The potential treatments listed below are currently under investigation. Their safety and effectiveness have not yet been established. An investigational drug must be proven safe and effective in clinical trials before it can be approved by the health authorities for prescription use or for use outside of an investigational research study.
Learn more about clinical trials and how they work.
About PROTAC® Protein Degraders:
Proteins are molecules that carry out important processes in our cells. However, sometimes certain proteins become damaged or too abundant, which can lead to disease. One of the ways the body naturally targets and eliminates harmful proteins is through the ubiquitin-proteasome system, or UPS. Arvinas is developing a way to make use of this process to destroy disease-causing proteins, called PROTAC® protein degraders. PROTAC® protein degraders have the potential to make use of the body’s natural disposal system to break down proteins that cause different diseases and are currently being studied in clinical trials.
The agents listed below are currently under investigation. Their safety and effectiveness have not yet been established.
Vepdegestrant is an investigational oral medicine which is a PROTAC® protein degrader designed to specifically target and degrade the estrogen receptor (ER). Estrogen receptors are proteins that can help promote the growth of certain types of cancer, including breast cancer.
Vepdegestrant is currently undergoing clinical trials to determine how well it works and how safe it is for treating ER-positive/HER2-negative breast cancer.
Vepdegestrant is believed to work by eliminating estrogen receptors, blocking estrogen activity, and potentially stopping tumor growth or causing shrinkage.
Currently Enrolling:
- VERITAC-2: A Study to Learn About a New Medicine Called vepdegestrant (ARV-471) (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer. (NCT05654623)
- This clinical trial is exploring if the investigational medication, ARV-471 (also known as vepdegestrant), works better than an approved therapy (fulvestrant) in prolonging the time without disease worsening in people living with advanced breast cancer.
- TACTIVE-U Umbrella Trial: A Study to Learn About the Study Medicine (vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. The TACTIVE-U study is divided into separate sub-studies focused on learning about the side effects and potential benefits of the investigational medicine vepdegestrant when given together with other medicines for potential treatment of advanced or metastatic breast cancer that has worsened after prior treatment.
- Sub-Study A (NCT05548127) will help us learn about the safety and effectiveness of vepdegestrant when taken with the approved breast cancer medicine abemaciclib (a CDK 4/6 inhibitor).
- Sub-Study B (NCT05573555) will help us learn about the safety and effectiveness of vepdegestrant when taken with the approved breast cancer medicine ribociclib (a CDK4/6 inhibitor).
- Sub-Study C (NCT06125522) will help us learn about the safety and effectiveness of vepdegestrant when taken with another medicine, samuraciclib (a CDK7 inhibitor).
- TACTIVE-K: A study to learn about vepdegestrant when given with PF-07220060 to people with advanced or metastatic breast cancer. (NCT0620837).
- This clinical trial can help us learn if the two potential treatments being studied, vepdegestrant and a CDK4 inhibitor (PF-07220060), are safe and effective in people with previously treated advanced or metastatic breast cancer.
If you are interested in learning more about these trials, please speak with your doctor and visit the website www.clinicaltrials.gov by clicking on the trial links above or contact us at +1-475-345-3366 or via email clinicaltrialsARV-471@arvinas.com
Please note above that NCT refers to the National Clinical Trial number assigned by clinicaltrials.gov.
In prostate cancer, the growth of cancer cells is driven by an increase of signals through the androgen receptor (AR). When testosterone attaches to an androgen receptor, it can cause cancer cells to grow.
ARV-766 is an investigational oral medicine which is a PROTAC® protein degrader designed to specifically target and degrade the androgen receptor (AR). ARV-766 works by causing androgen receptors to be eliminated, which blocks the activity of androgens and could potentially stop prostate tumors from growing or cause the tumors to shrink.
ARV-766 is currently undergoing clinical trials to determine how well it works and how safe it is for treating metastatic prostate cancer.
Currently Recruiting:
- Clinical Trial to Evaluate ARV-766 in Patients With Metastatic Prostate Cancer (NCT05067140). This clinical trial is divided into different sub-studies:
- ARV-766 Part A&B is evaluating the side effects and potential benefits of an investigational medication (ARV-766) and how prostate cancer responds to different doses of ARV-766 in men with metastatic castrate resistant prostate who have specific mutations.
- ARV-766 + Abiraterone Part C is assessing the potential benefits and side effects of how prostate cancer responds to investigational medication (ARV-766) in combination with abiraterone (an approved drug) in men with metastatic prostate cancer.
If you are interested in learning more about this trial, please speak with your doctor and visit the website www.clinicaltrials.gov by clicking on the trial links above or contact us at +1-475-345-3374 or via email at clinicaltrialsarv-766@arvinas.com.
Please note above that NCT refers to the National Clinical Trial number assigned by clinicaltrials.gov.
ARV-393 is an investigational oral medicine which is a PROTAC® protein degrader designed to specifically target and degrade a protein called B-cell lymphoma 6 (BCL6) that is present in many types of non-Hodgkin’s lymphomas and can become damaged or too abundant and promote the growth of certain types of cancer. ARV-393 is currently undergoing clinical trials to determine how well it works and how safe it is for treating non-Hodgkin’s lymphomas.
Currently Enrolling:
- A Phase 1 First-in-Human study of ARV-393 is being conducted on adult participants diagnosed with advanced Non-Hodgkin’s Lymphoma (NHL) (NCT06393738). This clinical trial aims to investigate the safety, and potential activity of the investigational drug ARV-393 in patients with advanced relapsed/refractory non-Hodgkin’s lymphoma.
If you are interested in learning more about this trial, please speak with your doctor and visit the website www.clinicaltrials.gov by clicking on the trial links above or contact us at +1-475-345-3374 or via email at clinicaltrialsARV-393@arvinas.com.
Please note above that NCT refers to the National Clinical Trial number assigned by clinicaltrials.gov.